<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C) has been used to treat older patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), but has resulted in complete remission for &lt;20% of cases </plain></SENT>
<SENT sid="1" pm="."><plain>A pilot study of the efficacy of a combination chemotherapy using low-dose ara-C, melphalan (Mel), and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> (Mit) was conducted </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: The treatment comprised ara-C (10 mg/m2) twice daily, melphalan (2 mg/body) every other day, and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> (3 mg/m2) every 3 days </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment was discontinued if the nuclear cell count was &lt;15,000/microl with &lt;20% blast count in the bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end-points were initial response and tolerability </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The study comprised 9 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (median age, 75 years) </plain></SENT>
<SENT sid="6" pm="."><plain>Complete remission was achieved in 3 patients </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients displayed grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>One patient died from <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The present regimen was more effective and displayed similar safety, compared with low-dose ara-C alone </plain></SENT>
</text></document>